Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected
mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in …

Matrix-M™ adjuvant is a key component of several novel vaccine candidates. The Matrix-M
adjuvant consists of two distinct fractions of saponins purified from the Quillaja saponaria …

Background Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75%
efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina …

Background Subcutaneous administration of the monoclonal antibody L9LS protected adults
against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal …

Background Malaria is a leading cause of morbidity and mortality worldwide. We previously
reported the efficacy of the R21/Matrix-M malaria vaccine, which reached the WHO-specified …

Background Despite a global epidemiological transition towards increased burden of non-
communicable diseases, communicable diseases continue to cause substantial morbidity …

Background Stalled progress in controlling Plasmodium falciparum malaria highlights the
need for an effective and deployable vaccine. RTS, S/AS01, the most effective malaria …

Background Malaria control remains a challenge in many parts of the Sahel and sub-Sahel
regions of Africa. Methods We conducted an individually randomized, controlled trial to …

Background CIS43LS is a monoclonal antibody that was shown to protect against controlled
Plasmodium falciparum infection in a phase 1 clinical trial. Whether a monoclonal antibody …

Background New approaches for the prevention and elimination of malaria, a leading cause
of illness and death among infants and young children globally, are needed. Methods We …